Last updated: March 6, 2026
What is NDC 00378-5089?
NDC 00378-5089 corresponds to a specific drug product listed in the National Drug Code (NDC) directory. Based on available data, it is identified as Doxycycline Hyclate tablets, typically used for bacterial infections. The product details specify the dose, packaging, manufacturer, and approved indications per the FDA records.
Market Size and Demand Analysis
Current Market Landscape
- Estimated annual sales: Approximately $150 million in the United States for doxycycline products, according to IQVIA data (2022).
- Patient population: An estimated 2.2 million prescriptions filled annually in the US, with demand stable over recent years.
- Main competitors: Generic doxycycline manufacturers dominate, including Teva, Sagent, Mylan, and Sun Pharmaceutical.
Key Market Segments
- Infections requiring doxycycline: Respiratory tract infections, sexually transmitted diseases, Lyme disease, and syphilis.
- Geographic distribution: Primarily concentrated in North America, with increasing interest in emerging markets due to antibiotic resistance concerns.
Regulatory & Reimbursement Environment
- FDA status: Approved as a generic antibiotic, no recent amendments or new indications.
- Reimbursement trends: Favorable, with most payers covering doxycycline with minimal restrictions under Tier 2 formularies.
- Pricing policy: Sensitive to generic competition with constrained margins.
Price Projection Factors
Drivers of Price and Volume
- Generic competition: Already intense; most brands retail at approximately $0.15 to $0.35 per tablet.
- Manufacturing costs: Relatively stable, with value margins shrinking due to price erosion.
- Regulatory conditions: No recent changes affecting market access or patent protections.
Price Trends and Forecast
| Year |
Average Price per Tablet |
Volume (million units) |
Total Market Value (USD millions) |
| 2022 |
$0.25 |
600 |
$150 |
| 2023 |
$0.24 |
610 |
$147 |
| 2024 |
$0.23 |
620 |
$142 |
| 2025 |
$0.22 |
630 |
$138 |
The decline in unit price is driven by increased competition and market saturation.
Price Projection Summary
- Short-term (next 1-2 years): Slight decrease in price per tablet (approximately 8-10%) due to ongoing generic competition.
- Medium-term (3-5 years): Further erosion is possible, potentially stabilizing around $0.20 per tablet if alternative formulations or shortages do not emerge.
- Long-term outlook: Minimal growth in revenue; the market is mature with low pricing elasticity.
Market Entry and Competition Strategies
- Differentiation: Enhanced formulations or extended-release versions are limited for doxycycline, reducing therapeutic differentiation.
- Pricing power: Marginal, driven mainly by manufacturing efficiencies and volume.
- Regulatory advantages: No recent patent protections, emphasizing reliance on cost leadership.
Risks and Uncertainties
- Patent litigations: No active patent challenges reported for this NDC.
- Antibiotic resistance: Could impact demand if new resistant strains emerge, prompting shifts toward alternative therapies.
- Regulatory changes: New guidelines for antibiotics could influence distribution and reimbursement.
Key Takeaways
- The drug represented by NDC 00378-5089 is a generic doxycycline tablet with a stable, high-volume market.
- Current pricing is approximately $0.25 per tablet, with downward pressure expected.
- Market growth remains flat due to saturation and consolidation among manufacturers.
- Entry barriers are low; competition is intense based on price.
FAQs
Q1: How does the price of this drug compare to other doxycycline products?
It is within the typical range of $0.15 to $0.35 per tablet, aligning with most generic versions.
Q2: Are there opportunities for brand-name premiums?
Limited, as no recent patent protections support premium pricing; generics dominate.
Q3: What factors could alter market dynamics?
Emergence of resistance, new formulation approvals, or regulatory restrictions could impact demand and pricing.
Q4: Is supply chain stability a concern?
No significant disruptions reported; manufacturing costs remain stable.
Q5: What is the outlook for the next five years?
Revenue is expected to decline gradually, with prices stabilizing around $0.20 per tablet as market saturation continues.
Sources
[1] IQVIA. (2022). Pharmaceutical Market Trends Data.
[2] U.S. Food and Drug Administration. (2022). Approved Drug Listings.
[3] Whitman, R. L., et al. (2022). Antibiotic resistance trends. Journal of Infectious Diseases.
